RepliCel Life Sciences Current ratio
Mi az RepliCel Life Sciences Current ratio?
A Current ratio az RepliCel Life Sciences, Inc. - 0.24
Mi a Current ratio meghatározása?
A jelenlegi arány likviditási mutató, amely azt méri, hogy a vállalatnak elegendő forrása van-e a rövid távú kötelezettségek teljesítéséhez.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio a Health Care szektor a TSXV-on cégekben a RepliCel Life Sciences -hoz képest
Mit csinál RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
current ratio -hoz hasonló cégek RepliCel Life Sciences
- Rochester Resources nak Current ratio 0.24 van
- Africa nak Current ratio 0.24 van
- Commonwealth Bank of Australia nak Current ratio 0.24 van
- Fatfish Blockchain nak Current ratio 0.24 van
- CBB nak Current ratio 0.24 van
- Mimi's Rock nak Current ratio 0.24 van
- RepliCel Life Sciences nak Current ratio 0.24 van
- Code Chain New Continent nak Current ratio 0.24 van
- Global Sweeteners nak Current ratio 0.24 van
- WebSafety nak Current ratio 0.24 van
- Lakes Oil NL nak Current ratio 0.24 van
- Firm Capital Property Trust nak Current ratio 0.24 van
- Burgundy Technology Acquisition nak Current ratio 0.24 van